secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2022-09-08T23:59:59+00:00
Accession:  0001628280-22-024587
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K
-----------------------------------------------------------------------------

- Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.
- Adjusted EBITDA $450K vs $422K; operating loss $284K includes $206K stock comp and $528K D&A.
- Gross margin 49% vs 52% due to higher study expenses and SaaS costs; bookings at record level.
- Cash $8.1M, no debt; net cash used in ops $195K, investing $754K for lab equipment.
- Alloy Therapeutics partnership delivered series of antibody hits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828022024587/0001628280-22-024587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828022024587/csbr-20220908.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-024587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer